相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2023)
European bio-naive spondyloarthritis patients initiating TNF inhibitor: time trends in baseline characteristics, treatment retention and response
Sara Nysom Christiansen et al.
RHEUMATOLOGY (2022)
Treatment Failure in Axial Spondyloarthritis: Insights for a Standardized Definition
Xavier Juanola et al.
ADVANCES IN THERAPY (2022)
Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
Roberta Ramonda et al.
RMD OPEN (2021)
One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study
Maria Sole Chimenti et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2020)
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
Santiago Rodrigues Manica et al.
ARTHRITIS RESEARCH & THERAPY (2020)
Treatment response and drug retention rates in 24 195 biologic-naive patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration
Lykke Midtboll Ornbjerg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors
Atul Deodhar et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
Xenofon Baraliakos et al.
RMD OPEN (2019)
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological diseasemodifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Desiree van der Heijde et al.
LANCET (2018)
Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis
Atul Deodhar et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a systematic literature review
Victoria Navarro-Compan et al.
RMD OPEN (2017)
Does the reason for discontinuation of a first TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort
Adrian Ciurea et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study
Arto V. Heinonen et al.
JOURNAL OF RHEUMATOLOGY (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register
E. Lie et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
Martin Rudwaleit et al.
ARTHRITIS RESEARCH & THERAPY (2010)
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
C. Lukas et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Treatment response to a second or third TNF-inhibitor in RA:: results from the South Swedish Arthritis Treatment Group Register
J. A. Karisson et al.
RHEUMATOLOGY (2008)
Efficacy and safety of adalimumab in patients with ankylosing spondylitis - Results of a multicenter, randomized, double-blind, placebo-controlled trial
Desiree van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2006)
The LUNDEX, a new index of drug efficacy in clinical practice - Results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden
LE Kristensen et al.
ARTHRITIS AND RHEUMATISM (2006)
Efficacy and safety of infliximab in patients with ankylosing spondylitis - Results of a randomized, placebo-controlled trial (ASSERT)
D van der Heijde et al.
ARTHRITIS AND RHEUMATISM (2005)
分享论文
